skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures



Expert Opinion

(6655) Total Article Views


Authors: Weisenberg JLZ, Wong M

Published Date July 2011 Volume 2011:7(1) Pages 409 - 414
DOI: http://dx.doi.org/10.2147/NDT.S14208

Judith LZ Weisenberg, Michael Wong
Department of Neurology, Washington University School of Medicine, St Louis, MO, USA

Abstract: Epilepsy is a common disease with significant morbidity and mortality. Approximately one-third of patients with epilepsy are refractory to available seizure medications, emphasizing the need to develop better drugs with novel mechanisms of action. Ezogabine, also known as retigabine, is a new potential adjunctive treatment for adults with intractable partial seizures. Ezogabine has a unique mechanism of action consisting of activating KCNQ2/3 (Kv7) potassium channels. Ezogabine has undergone a number of Phase II and III trials demonstrating efficacy at 600,900 and 1200 mg/day in a dose-dependent fashion. The most common adverse events with ezogabine are central nervous system effects, particularly dizziness and somnolence. Urologic symptoms, particularly urinary retention, represent a rare but unique side effect of ezogabine. Ezogabine is predominantly metabolized via glucuronidation. Its half-life is 8 hours, suggesting a need for three-times-a-day administration. Ezogabine exhibits minimal interactions with other seizure medications, except possibly lamotrigine. Ezogabine has potential for clinical applications in other medical conditions beyond epilepsy, such as neuropathic pain, neuromyotonia, and bipolar disease, but these are based primarily on experimental models.

Keywords: antiepileptic drug, epilepsy, ezogabine



Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter

 

Other articles by Dr Michael Wong


Readers of this article also read: